Lonza Group Stock

Lonza Group EBIT per Share

The EBIT per Share of Lonza Group (LONN.SW) as of Aug 14, 2026 is 19.69 CHF. In the previous year, EBIT per Share was 13.01 CHF — a change of 51.41% (higher).

EBIT per Share

19.69CHF

YoY

51.41%

Last updated:

EBIT per Share of Lonza Group is 2026 19.69 CHF. EBIT per Share of Lonza Group was 2025 13.01 CHF. It decreases by 51.41% higher compared to the previous year.
Access this data via the Eulerpool API

Lonza Group Stock analysis

What does Lonza Group do? The Lonza Group AG is a global company based in Basel, Switzerland. It was founded in 1897 and has since had a long history of operational excellence and innovation. Lonza is a leading provider of customized chemical and biotechnological solutions and services for customers in the health, agrochemical, life science, and other sectors. Lonza's business model is based on providing customized, customer-oriented solutions for complex chemical and biological challenges. The company focuses on three main divisions: Pharma & Biotech, Consumer Health, and Specialty Ingredients. Within these divisions, Lonza offers a variety of products, services, and solutions tailored to meet the specific needs of its customers. In the Pharma & Biotech division, Lonza offers a wide range of products and services for the pharmaceutical and biotechnology industries. The company is a global leader in active ingredients for the pharmaceutical industry and also provides custom process development and manufacturing services for biopharmaceuticals and small molecules. In the Consumer Health division, Lonza develops and produces a variety of dietary supplements, cosmetic products, and household products for its customers. The company is a recognized expert in the formulation and production of high-quality dietary supplements and has also established a strong position in the production of natural cosmetic products in recent years. Lonza's Specialty Ingredients division offers a wide range of chemical and biotechnological products and services for the life science and specialty chemical industries. This includes products and services such as microbial control, material protection, custom development services, and others. Lonza is a leading manufacturer and supplier of dietary supplements, pharmaceutical active ingredients, agrochemicals, cosmetic ingredients, and other chemical and biotechnological products. The company has extensive expertise in process development and optimization, as well as in the manufacturing of products for various industries. One of Lonza's key products is the active ingredient Mipomersen, which is used in the treatment of familial hypercholesterolemia. Lonza is also a major provider of dietary supplements, particularly vitamins, minerals, omega-3 fatty acids, and other nutrients that can promote and support human health. Another important product of Lonza is the biosimilar component recombinant human insulin, which is used in the treatment of diabetes. Overall, Lonza is an innovative and leading company in the field of chemistry and biotechnology. With a strong focus on customer-oriented solutions and a broad portfolio of products and services, the company is well positioned to meet the growing demand for chemical and biological solutions in various industries. Lonza Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lonza Group stock

EBIT per Share of Lonza Group is 19.69 CHF in 2026.

EBIT per Share of Lonza Group changed from 13.01 CHF to 19.69 CHF, representing a 51.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Lonza Group since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

Income Statement — Lonza Group

All Key Metrics — Lonza Group